Loading stock data…
Enlivex Ltd. (ENLV)
$1.11+0.01 (+0.91%)
Market ClosedLast close Sep 8
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enlivex Ltd. in the Healthcare sector is trading at $1.11 with a market capitalization of $19M. Wall Street consensus targets $80.00 (1 analysts), implying a +7107.2% move over the next 12 months. The stock is currently near its 52-week low of $1.02, remaining 90.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +7107.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 26) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.86M↓ | -$2.56M↑ | -$3.08M↑ | -$3.50M↑ | -$4.88M |
| Net Income | $1.24B↑ | -$2.21M↓ | -$1.87M↑ | -$3.45M↑ | -$5.18M |
Peer Comparison
JNJUNHPFE
Fundamentals
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM int...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.41M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.00
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
63.85%
Volume
Today's trading volume
189,701
Recent News
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Enlivex Ltd. (ENLV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
Enlivex Ltd. (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Enlivex Ltd. (ENLV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA
Investing.com -- The FDA has granted Regenerative Medicine Advanced Therapy designation to Enlivex's experimental immunotherapy Allocetra for age-related knee osteoarthritis, Investing.com has learned.
Enlivex advances Allocetra while expanding into prediction markets
Enlivex CEO Oren Hershlovitz joined Steve Darling from Proactive to discuss the company’s dual strategy of advancing late-stage clinical drug development while building a digital asset treasury initiative tied to decentralized prediction markets. Hershkovitz explained that Enlivex continues progressing development of Allocetra for osteoarthritis while simultaneously gaining exposure to the growing prediction market sector through the RAIN token ecosystem. The company completed a transformative transaction at the end of 2025 that established a treasury strategy centered around the RAIN protocol, which management describes as a decentralized prediction market platform. Enlivex invested more than $200 million in RAIN tokens and also secured an exclusive option to acquire additional tokens at a fixed price. Hershkovitz said the structure provides shareholders with significant upside exposure tied to the future growth of the protocol and broader adoption of decentralized prediction markets. On the clinical side, Enlivex continues advancing Allocetra™ for knee osteoarthritis. The company previously completed a Phase 2a double-blind, placebo-controlled study that demonstrated statistically significant improvements in pain reduction and functional outcomes among patients over the age of 64. Enlivex has now received authorization from the U.S. Food and Drug Administration to begin a Phase 2b study and has also secured Clinical Trial Application approval in Denmark. Topline results from the Phase 2b trial are expected in the first half of 2027 and could support advancement into Phase 3 development. The company believes its combination of biotechnology development and strategic exposure to emerging digital asset infrastructure creates a differentiated growth profile as both sectors continue to evolve. #proactiveinvestors #enlivixltd #nasdaq #enlv #Biotech #Allocetra #Osteoarthritis #ClinicalTrials #PredictionMarkets #DigitalAssets #RAINToken #HealthcareInnovation